Catalyst Pharmaceuticals, Inc.
HealthcareNASDAQ:CPRX · NASDAQ Capital Market
-$0.01 today
Vol 0.78M · Avg 2.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
22.5%
avg 1.7%
ROIC
20.3%
avg -1.5%
ROA
19.4%
avg 0.5%
Analysis
ROE is currently the strongest return metric at 22.5% versus its period average of 1.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard John Daly | President, Chief Executive Officer & Director | $1.61M | — | 65 | $281,843.00 | 0.23% |
Michael W. Kalb | Executive Vice President, Treasurer & Chief Financial Officer | $1.02M | — | 55 | $13,665.00 | 0.01% |
Steven R. Miller | Executive Vice President, Chief Operating Officer & Chief Scientific Officer | $969,200.00 | — | 64 | $1.47M | 1.20% |
Jeffrey Del Carmen | Executive Vice President & Chief Commercial Officer | $948,248.00 | — | 55 | $1.04M | 0.85% |
Preethi Sundaram | Chief Strategy Officer | $753,425.00 | — | 50 | $57,173.00 | 0.05% |
William T. Andrews FACP | Chief Medical Officer | $535,498.00 | — | 61 | $2,309.00 | <0.01% |
Brian Elsbernd | Chief Compliance Officer & Chief Legal Officer | $311,416.00 | — | 62 | $956,142.00 | 0.78% |
Patrick J. McEnany | Co-Founder & Non-Executive Chairman | $193,813.00 | — | 79 | $4.18M | 3.41% |
Angie Bechan | Executive VP & Chief Corporate Affairs Officer | — | — | — | — | — |
Mary Coleman | Vice President & Head of Investor Relations | — | — | — | — | — |
Paul Friel | Executive Vice President of Corporate Operations | — | — | — | — | — |
Gregg Russo | Chief Human Resources Officer | — | — | 63 | $687.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$908,000.00
Sells
10
$5.81M
Net Sentiment
$4.90M
Net selling
Most Active
Elsbernd Brian
4 transactions
1–10 of 11
Analysis
Insiders reported 1 buys worth $908,000.00 and 10 sells worth $5.81M over the last 12 months. That adds up to net selling of $4.90M. Elsbernd Brian was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
Who manages CPRX?
Catalyst Pharmaceuticals, Inc. (CPRX) lists 12 active executives. The top listed executive is Preethi Sundaram, Chief Strategy Officer.
Are CPRX insiders buying or selling?
Recent insider activity shows net buying of $6.79M.
Explore More
Continue the stock analysis
Jump to another research area for this company.